title: Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases.
abstract: Few data exist on the etiology, presentation, prognosis, and management of fungal endophthalmitis (FE) in cancer patients. FE cases were identified by reviewing the ophthalmology reports and microbiology cultures of patients at The University of Texas M. D. Anderson Cancer Center. We retrospectively reviewed the medical records and obtained information related to malignancy, fungal infection and its management, visual outcome, and mortality. We compared FE caused by Candida spp. (CE) to FE caused by molds (ME). Of the 102 cancer patients with a fungal infection for whom an ophthalmology consult was requested, 23 met the criteria for definite (N = 6) or probable (N = 17) FE (8 with CE, 15 with ME). All of the patients with ME had hematologic malignancies, whereas half of the patients with CE had solid tumor (P = .008). Only patients with CE had a history of surgery within 30 days of FE diagnosis (38%, P = .03). Fungal pneumonia [17 (74%)] and disseminated infection [14, (61%)] were common. The most common presenting symptoms were decreased vision [16 (70%)] and ocular pain [14 (61%)]. All treated patients received systemic antifungals (combination therapy in 72% of the cases). Seven patients (30%) underwent vitrectomy. Only one patient received intraocular injection of amphotericin B along with systemic antifungals. Four-week mortality was high [13 (57%)], especially in ME (73%, P = .04). Among the eight surviving patients where visual acuity could be assessed, visual outcome improved or remained stable in five (63%). FE in cancer patients occurs in the setting of severe, frequently disseminated opportunistic mycoses, is caused predominantly by hyalohyphomycetes, and is a marker for high 4-week mortality.
authors.affiliation: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: G A
authors.initials: GA
authors.lastname: Lamaris
authors.forename: B
authors.initials: B
authors.lastname: Esmaeli
authors.forename: G
authors.initials: G
authors.lastname: Chamilos
authors.forename: A
authors.initials: A
authors.lastname: Desai
authors.forename: R F
authors.initials: RF
authors.lastname: Chemaly
authors.forename: I I
authors.initials: II
authors.lastname: Raad
authors.forename: A
authors.initials: A
authors.lastname: Safdar
authors.forename: R E
authors.initials: RE
authors.lastname: Lewis
authors.forename: D P
authors.initials: DP
authors.lastname: Kontoyiannis
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida / Q000302:isolation & purification; D009877:Endophthalmitis / Q000382:microbiology* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D005260:Female; D005658:Fungi / Q000302:isolation & purification; D006761:Hospitals; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D009369:Neoplasms / Q000150:complications*; D011014:Pneumonia / Q000382:microbiology; D011183:Postoperative Complications; D012189:Retrospective Studies; D012307:Risk Factors; D013781:Texas; D014821:Vitrectomy
chemical_list: D000935:Antifungal Agents